ATE273979T1 - Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis - Google Patents

Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis

Info

Publication number
ATE273979T1
ATE273979T1 AT01907784T AT01907784T ATE273979T1 AT E273979 T1 ATE273979 T1 AT E273979T1 AT 01907784 T AT01907784 T AT 01907784T AT 01907784 T AT01907784 T AT 01907784T AT E273979 T1 ATE273979 T1 AT E273979T1
Authority
AT
Austria
Prior art keywords
osteoporosis
treatment
xanthine derivatives
intermediate products
derivatives
Prior art date
Application number
AT01907784T
Other languages
English (en)
Inventor
Guenter Johannes Billen
Yamina Bouali
Francois Nique
Yusuke Satoh
Jean-Paul Vevert
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE273979T1 publication Critical patent/ATE273979T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01907784T 2000-02-15 2001-02-14 Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis ATE273979T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0001845A FR2804958B1 (fr) 2000-02-15 2000-02-15 Derives de xanthine, leur procede de preparation et les intermediaires de ce procede, leur application comme medicament et les compositions pharmaceutiques les renfermant
PCT/FR2001/000420 WO2001060824A1 (fr) 2000-02-15 2001-02-14 Derives de xanthine, intermediaires et application au traitement de l'osteoporose

Publications (1)

Publication Number Publication Date
ATE273979T1 true ATE273979T1 (de) 2004-09-15

Family

ID=8847004

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01907784T ATE273979T1 (de) 2000-02-15 2001-02-14 Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis

Country Status (9)

Country Link
EP (1) EP1257552B1 (de)
AT (1) ATE273979T1 (de)
AU (1) AU2001235668A1 (de)
DE (1) DE60104986T2 (de)
DK (1) DK1257552T3 (de)
ES (1) ES2227134T3 (de)
FR (1) FR2804958B1 (de)
PT (1) PT1257552E (de)
WO (1) WO2001060824A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009091A1 (en) 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
NZ613219A (en) 2008-01-04 2014-11-28 Intellikine Llc Heterocyclic containing entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
UA115767C2 (uk) 2011-01-10 2017-12-26 Інфініті Фармасьютікалз, Інк. Способи отримання ізохінолінонів і тверді форми ізохінолінонів
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2015003881A1 (en) * 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
KR20190033526A (ko) 2016-06-24 2019-03-29 인피니티 파마슈티칼스, 인코포레이티드 병용 요법
CN109503583A (zh) * 2018-12-14 2019-03-22 南京纽邦生物科技有限公司 1,7-二甲基黄嘌呤及其中间体的制备方法、中间体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE176470T1 (de) * 1990-10-18 1999-02-15 Kyowa Hakko Kogyo Kk Xanthinderivate
EP0825993A1 (de) * 1995-05-19 1998-03-04 Chiroscience Limited Xanthine und ihre therapeutische anwendung
JPH09169665A (ja) * 1995-12-21 1997-06-30 Kenichi Miyamoto 骨粗鬆症治療剤
SI0812844T1 (en) * 1996-06-07 2003-02-28 Hoechst Aktiengesellschaft Use of theophyllin derivatives for the treatment and prophylaxis fo shock conditions, novel xanthine compounds and processes for the production thereof
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
JPH1192379A (ja) * 1997-07-24 1999-04-06 Kunio Takaoka 骨疾患の予防または治療剤

Also Published As

Publication number Publication date
EP1257552B1 (de) 2004-08-18
FR2804958A1 (fr) 2001-08-17
DE60104986D1 (de) 2004-09-23
ES2227134T3 (es) 2005-04-01
PT1257552E (pt) 2005-01-31
WO2001060824A1 (fr) 2001-08-23
AU2001235668A1 (en) 2001-08-27
DE60104986T2 (de) 2005-08-25
DK1257552T3 (da) 2004-12-20
EP1257552A1 (de) 2002-11-20
FR2804958B1 (fr) 2005-07-08

Similar Documents

Publication Publication Date Title
ATE235459T1 (de) Derivate von aminosäuren, sie enthaltende pharmazeutische zusammensetzungen sowie deren herstellunsgverfahren
AR024390A1 (es) Nuevos compuestos
ATE202702T1 (de) Verwendung von oestrogenagonisten und - antagonisten zur herstellung eines medikaments zur behandlung von atherosklerose, unabhängig von lipidsenkung
DE68914292T2 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
DE69607650T2 (de) 2,3,5-trimethyl-hydroxyanilid-derivative, ihre herstellung und ihre theraoeutische verwendung
ATE273979T1 (de) Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis
ATE231160T1 (de) Erythromycin-derivate, ihr verfahren zur herstellung und ihre verwendung als arzneimittel
DK0450420T3 (da) Heterocyclisk substituerede dihydropyridiner, fremgangsmåde til deres fremstilling og deres anvendelse i lægemidler
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
DK0625153T3 (da) Nyt isoindolinonderivat, dets fremstilling og farmaceutiske præparater med et indhold deraf
ATE308533T1 (de) Zwischenprodukt und verfahren zur teilsynthese von paclitaxel und dessen analogen
ZA939118B (en) Processes for preparing 2-cyano-3-hydroxy-propenamides and pharmaceutical compositions containing them
ATE267832T1 (de) Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
DE59606725D1 (de) Substituierte phenylamidine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
DE69002340D1 (de) Pyrimidin-derivate, 2-(4-(alpha-heteroaryl-alpha-aryl-(alpha-alkyl)-methoxy)-butyl)-1-piperazinyl) mit serotoninergischer wirkung.
ATE56437T1 (de) Verfahren zur herstellung von 1,4dihydropyridinderivaten ueber neue zwischenprodukte.
ATE79752T1 (de) Verwendung von chromanderivaten zur herstellung eines medikamentes zur behandlung von depressiven zustaenden.
DE60019723D1 (de) Eine methode zur herstellung von verbindungen der formel 1 und derivaten
AR022044A1 (es) Derivados de 1,5-benzodiazepina
HUP0001127A2 (hu) Eljárás N-[5-difenil-foszfinoil-metil-4-(4-fluor-fenil)-6-izopropil-pirimidin-2-il]-N-metil-metánszulfonamid előállítására
ES2095058T3 (es) Derivados del 3-azabiciclo(3.2.0)heptano substituidos como productos intermedios.
NO305116B1 (no) Fremgangsmate for fremstilling av C-substituerte dietylentriaminer
DE69610331D1 (de) Neue gylcylanilid-derivate, deren herstellung und deren verwendung zur behandlung von hypercholesterolämie und atherosklerose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1257552

Country of ref document: EP